{"Title": "Differentiation therapy for glioblastoma\u2013too many obstacles?", "Year": 2016, "Source": "Mol. Cell. Oncol.", "Volume": "3", "Issue": 2, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 7, "DOI": "10.1080/23723556.2015.1124174", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85050730895&origin=inward", "Abstract": "\u00a9 2016, \u00a9 2016 The Author(s). Published with license by Taylor & Francis Group, LLC. \u00a9 2016, \u00a9 Helena Car\u00e9n, Stephan Beck, and Steven M. Pollard.The therapeutic potential of differentiation therapy for glioblastoma will depend on the robustness and stability of the differentiated state. We recently reported several obstacles to bone morphogenetic protein (BMP)-induced differentiation therapy. Improved understanding of the mechanisms that tumor cells use to escape differentiation commitment is urgently needed.", "AuthorKeywords": ["Astrocyte", "BMP", "differentiation", "DNA methylation", "epigenetics", "Glioblastoma", "neural stem cell", "oligodendrocyte"], "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85050730895", "SubjectAreas": [["Molecular Medicine", "BIOC", "1313"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"35081819900": {"Name": "Car\u00e9n H.", "AuthorID": "35081819900", "AffiliationID": "60079626, 60016437, 60027675", "AffiliationName": "Sahlgrenska Cancer Center, Department of Pathology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg"}, "57193033325": {"Name": "Beck S.", "AuthorID": "57193033325", "AffiliationID": "60109234, 60022148", "AffiliationName": "Department of Cancer Biology, UCL Cancer Institute, University College London"}, "10040672100": {"Name": "Pollard S.", "AuthorID": "10040672100", "AffiliationID": "60014873, 60027272", "AffiliationName": "MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh bioQuarter"}}}